David R. Spigel, MD, FASCO

President and Chief Medical Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch

[Zach Klaassen @zklaassen_md]

Safety/efficacy of JNJ-6143, a first-in-class RIPTAC in heavily pre-Rxed pts with mCRPC @BGarmezy @urotoday #ESMO26

🚨Ph 1 n=105; RP2D: 50 mg
🚨At 50 mg:
- <60% any-grade TRAEs
- 77% PSA50; 48% PSA90
- High PSA RR irrespective of HR molecular features
- 69% ORR

[David R. Spigel, MD, FASCO @DavidRSpigel]

Fantastic discussion!

[Alfredo Addeo MD @Alfdoc2]

🎯 #ESMO26 | Excellent discussion by @benlevylungdoc on SARON and PERSEE!
Two trials, two important lessons for advanced NSCLC.
🔹 SARON: Consolidative radiotherapy improved PFS and local disease control in oligo metastatic NSCLC, but no OS benefit (HR 0.99).
🔹 PERSEE: Pembrolizumab + chemo met its primary endpoint PFS but not OS though numerically better (not powered for OS) in PD-L1 ≥50% NSCLC.
Key messages from @benlevylungdoc :
• Oligometastatic disease needs better biological definition, beyond the number of lesions.
• Treatment intensification should be guided by better patient selection.
• More treatment does not automatically mean better outcomes!
- Lower threshold to add chemo to pembro in PD-L1 >50%
👏 A thoughtful discussion with practical implications for our clinics.
#ESMOAmbassador #LungCancer #NSCLC

[Toni Choueiri, MD @DrChoueiri]

Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12.7 months (HR 0.42). A major advance for patients with SCLC! #ESMO26 @oncoalert @myESMO

[NEJM @NEJM]

Presented at #ESMO26:

Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: https://t.co/8KxJzxKpQZ

@myESMO

[Sarah Cannon Docs @SarahCannonDocs]

At #ESMO26, SCRI will present 85+ abstracts and presentations across antibody drug conjugates, immunotherapies, and bispecific antibodies, with work from 40 authors across our network of research sites. https://t.co/ikVbXDSTuj

[NEJM @NEJM]

Presented at #ESMO26:

In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: https://t.co/A4dduLqRn1

@myESMO

[Sarah Cannon Docs @SarahCannonDocs]

Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for patients with KRAS G12C-mutated lung cancer. https://t.co/Qz6C2ERZGr

[David R. Spigel, MD, FASCO @DavidRSpigel]

@MLJohnsonMD2 gives a perfect discussion of #ADCs in NSCLC oral session at #esmo26 - a fast-evolving and important next chapter in LC research @SarahCannonDocs

[David R. Spigel, MD, FASCO @DavidRSpigel]

@ErikaHamilton9 discussing innovative drugs in mBC - expert review of emerging landscape! #esmo26 @SarahCannonDocs

[David R. Spigel, MD, FASCO @DavidRSpigel]

@BGarmezy presenting incredible Ph I data in mCRPC with JNJ-6143 (RIPTAC): 75% ORR (incl CRs - heavily pretreated). Ph 2 underway. #ESMO26 @SarahCannonDocs

[Sarah Cannon Docs @SarahCannonDocs]

Expanding access to clinical trials remains a critical priority in oncology research. @SPremji7866 of SCRI recently shared insights with @TargetedOnc on the importance of community-based research and the evolving breast cancer landscape.

https://t.co/x3qW1DnWxj

[Sarah Cannon Docs @SarahCannonDocs]

Congratulations to @IMFmyeloma on the launch of the US Myeloma Network! We are honored to serve as the CRO and support clinical trials designed to advance research and expand opportunities for patients w/ multiple myeloma. Looking forward to this collaboration in #CancerResearch.

[David R. Spigel, MD, FASCO @DavidRSpigel]

@MeredithMcKean joined by Dr. Marlana Orloff (#SKCCC @JeffersonUniv) delivering expert review of darovasertib/crizotinib data in uveal melanoma session at #ESMO26

[David R. Spigel, MD, FASCO @DavidRSpigel]

@MeredithMcKean delivering state-of-the-art talk on advances in uveal melanoma at #ESMO26

[Sarah Cannon Docs @SarahCannonDocs]

In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access.
Read the Q&A:

[CancerTherapyAdvisor @CancerTherAdvsr]

Breaking from #ASCO26: The Phase 3 #frontMIND trial successfully hit its primary endpoint! 🚨

Adding tafasitamab + lenalidomide to standard R-CHOP significantly improves PFS in newly diagnosed high-risk #DLBCL.

Full story: https://t.co/yuYq3TdwOT

[Sarah Cannon Docs @SarahCannonDocs]

What research is generating buzz heading into #ASCO26? In a new @biospace feature, Dr. @MeredithPelster of Sarah Cannon Research Institute shares insights on promising advances in pancreatic cancer research and targeted therapies.

https://t.co/5JBDOJOKRO

[Sarah Cannon Docs @SarahCannonDocs]

Inspiring discussion around how we can have greater impact in the community for veterans w/ our colleagues at #FCS & the VA @Dee_Anna_Smith @LucioGordanMD #ASCO26

[Sarah Cannon Docs @SarahCannonDocs]

Meet SCRI experts at #ASCO26 for a lymphoma session led by @KrishPatelMD . Join the conversation and learn how we are advancing research for patients.

[Sarah Cannon Docs @SarahCannonDocs]

SCRI contributed to research leading to upcoming plenary on Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with met pancreatic adenocarcinoma: Primary analysis from the phase 3 RASolute 302 @MeredithPelster @SCRIOncology #ASCO26